After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Bruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Good day and welcome to the Vertex Pharmaceuticals fourth quarter of 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Vertex said the company is also evaluating using suzetrigine in peripheral neuropathic pain. The approval of the drug was not a surprise to analysts, who also appeared to play down the cost.

It could play a role in reducing the overall exposure to opioids.” Whether doctors reach for the drug will most likely depend ...

Amazon is officially in the quick commerce arena, with its service available in parts of Bengaluru. This and more in today’s ETtech Morning Dispatch.

The Paris AI Action Summit, under the banner of ethical AI innovation, appears disconnected from the realities of how ...